Chest
-
COPD Comorbidity PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The Baseline (BDI) and Transition Dyspnea Index (TDI) are interview-based multidimensional instruments to assess breathlessness in patients with COPD. However, BDI/TDI interviewer process may introduce bias in the interpretation, leading to more variability in results. Innovative self-administered computerized (SAC) versions of the BDI/TDI were developed and validated for the BLAZE study which allows patients to provide direct ratings of breathlessness based on activities of daily living. ⋯ Anthony D'Urzo: Consultant fee, speaker bureau, advisory committee, etc.: AD has received research, consulting and lecturing fees from GlaxoSmithkline, Sepracor, Schering Plough, Altana, Methapharma, AstraZeneca, ONO pharma, Merck Canada, Forest Laboratories, Novartis Canada/USA, Boehringer Ingelheim (Canada) Ltd, Pfizer Canada, SkyePharma, and KOS Pharmaceuticals. Donald Mahler: Consultant fee, speaker bureau, advisory committee, etc.: The presenting author is a consultant for GlaxoSmithKline, Novartis, and Sunovion, and have served on Advisory Boards for Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pearl, and Sunovion, The C linical Trials Office at Dartmouth-Hitchcock Medical C enter (DHMC ) is currently receiving grants for clinical trials from Boehringer Ingelheim, Novartis, and Sunovion; Donald A. Mahler, M.D. is the DHMC principal investigator for these studies. Tracy White: Employee: Novartis employee Vijay Alagappan: Employee: Novartis employee Hungta Chen: Employee: Novartis employee Karoly Kulich: Employee: Novartis employee Nicola Gallagher: Employee: Novartis employee Donald Banerji: Employee: Novartis employee The following authors have nothing to disclose: Vanessa BrunelClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA 149 is in the late stage phase 3 trials prior to approval.
-
Asthma PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Aspirin Exacerbated Respiratory Disease (AERD) is commonly associated with chronic rhinosinusitis with nasal polyps (CRSwNP). Few information is available on the correlation between aspirin sensitivity and severe asthma. The aim of this study was to investigate the association between aspirin sensitivity and severe asthma and the presence of CRSwNP in a cohort of asthmatic patients. ⋯ The following authors have nothing to disclose: Jose Castillo, Cesar Picado, Vicente Plaza, Gustavo Rodrigo, Berta Juliá, Joaquim MullolNo Product/Research Disclosure InformationClinicalTrials.gov ID: NCT01513837.
-
COPD Rehabilitation PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Chronic obstructive pulmonary disease (COPD) impacts negatively on the quality of life of patients. Several studies have shown that acute exacerbations (AEs) decrease health-related quality of life, pulmonary function and survival of COPD patients. The objective of the present study was to examine the effects of a physical therapy program on quality of life in COPD patients hospitalized due to an acute exacerbation. ⋯ The following authors have nothing to disclose: Irene Torres-Sánchez, Marie Carmen Valenza, Gerald Valenza-Demet, Irene Cabrera-Martos, María José Flores-Barba, Angela Ruíz-SáezNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Dyspnea, the most distressing symptom experienced by COPD patients, is not always adequately relieved by bronchodilator monotherapy. The BLAZE study evaluated the superiority of QVA149, a dual bronchodilator combining the long-acting β2-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium, versus placebo and tiotropium for improvement in direct patient-reported dyspnea as assessed by the innovative self-administered computerized baseline and transition dyspnea index (SAC-BDI/TDI). ⋯ Anthony D'Urzo: Consultant fee, speaker bureau, advisory committee, etc.: Novartis, AstraZeneca, Forest Laboratories, Pfizer, Schering Plough, Grant monies (from industry related sources): GSK, Schering Plough, Methapharma, AstraZeneca, Merck Canada, Forest Laboratories, Novartis Donald Mahler: Consultant fee, speaker bureau, advisory committee, etc.: consultant for GlaxoSmithKline, Novartis, and Sunovion, and have served on Advisory Boards for Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pearl, and Sunovion, Grant monies (from industry related sources): receiving grants for clinical trials from Boehringer Ingelheim, Novartis, and Sunovion Tracy White: Employee: Novartis Pharmaceuticals Corporation Vijay Alagappan: Employee: Novartis Pharmaceuticals Corporation Hungta Chen: Employee: Novartis Pharmaceuticals Corporation Karoly Kulich: Employee: Novartis Pharma AG Nicola Gallagher: Employee: Novartis Horsham Research Centre Donald Banerji: Employee: Novartis Pharmaceuticals Corporation The following authors have nothing to disclose: Heinrich WorthClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
Critical Care Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: TTP was once recognized for its classic pentad features of fever, thrombocytopenia, microangiopathic hemolytic anemia, neurologic dysfunction and renal impairment. However TTP may present with atypical features and the diagnosis may be unrecognized. ⋯ The following authors have nothing to disclose: Ma. Theresa Bautista, Jay Steingrub, Ramakant sharmaNo Product/Research Disclosure Information.